anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will receive GDC-0927 orally as a single dose on Day -7. Continuous daily dosing will commence on Day 1. Depending on safety and tolerability, participants will be assigned sequentially to escalating doses of GDC-0927 with use of a standard 3 + 3 design. The starting dose will be 600 milligrams per day (mg/day), followed by dose escalation in 400 milligrams (mg) increments.
Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. They will also receive the new recommendations relating to complementary feeding through an educational device in the form of a smartphone application. This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd month until the 36th month of the child. Parents will also receive generic information (48 messages) contained in the health record and in connection with the general development.
Infected wound healing remains a challenging task in clinical practice due to several factors: (I) drug-resistant infections caused by various pathogens, (II) persistent inflammation that hinders tissue regeneration and (III) the ability of pathogens to persist intracellularly and evade antibiotic treatment. Microneedle patches (MNs), recognized for their effecacious and painless subcutaneous drug delivery, could greatly enhance wound healing if integrated with antibacterial functionality and tissue regenerative potential. A multifunctional agent with subcellular targeting capability and contained novel antibacterial components, upon loading onto MNs, could yield excellent therapeutic effects on wound infections. In this study, we sythesised a zeolitic imidazolate framework-8 nanoparticles (ZIF-8 NPs) loaded with low molecular weight fucoidan (Fu) and further coating by hyaluronic acid (HA), obtained a multifunctional HAZ@Fu NPs, which could hinders Methicillin-resistant Staphylococcus aureus (MRSA) growth and promotes M2 polarization in macrophages. We mixed HAZ@Fu NPs with photocrosslinked gelatin methacryloyl (GelMA) and loaded it into the tips of the MNs (HAZ@Fu MNs), administered to mice model with MRSA-infected full-thickness cutaneous wounds. MNs are able to penetrate the skin barrier, delivering HAZ@Fu NPs into the dermal layer. Since cells within infected tissues extensively express the HA receptor CD44, we also confirmed the HA endows the nanoparticles with the ability to target MRSA in subcellular level. In vitro and in vivo murine studies have demonstrated that MNs are capable of delivering HAZ@Fu NPs deep into the dermal layers. And facilitated by the HA coating, HAZ@Fu NPs could target MRSA surviving at the subcellular level. The effective components, such as zinc ions, Fu, and hyaluronic acid could sustainably released, which contributes to antibacterial activity, mitigates inflammation, promotes epithelial regeneration and fosters neovascularization. Through the RNA sequencing of macrophages post co-culture with HAZ@Fu, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis reveals that the biological functionalities associated with wound healing could potentially be facilitated through the PI3K-Akt pathway. The results indicate that the synergistic application of HAZ@Fu NPs with biodegradable MNs may serve as a significant adjunct in the treatment of infected wounds. The intricate mechanisms driving its biological effects merit further investigation.
Volunteers will receive three (3) intramuscular injections into the deltoid muscle of 0.5mL of of the Sm14+ GLA-SE vaccine on D0, W4 and W8. (D = Day; W = Week). (Vaccination schedule used in previous phases).
Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 50 mg qd. This arm evaluates the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of this dose level.
Information about pregnant women and their fetuses/infants, including the medical history, prenatal, perinatal, and postpartum periods (6 weeks after delivery) and throughout the treatment (e.g.surgery) for the child's medical condition (up to approx. child is @ 6 months of age), will be collected in this repository. The analysis of this information may help in understanding of the causes of fetal anomalies.
FIELD: medicine. SUBSTANCE: hepatoprotective product is suggested in tabletted form containing a substance covered with a multi-layer membrane. The core of tablets contains additional substances except silimarine as an active product at the quantity of 10-20% against core's weight. These tablets are of high velocity to release an active substance. EFFECT: higher efficiency of hepatoprotective action. 1 dwg, 3 tbl
BACKGROUND: Cardiogenic shock (CS) is the most severe form of acute heart failure. Discrepancies have been reported between sexes regarding delays, pathways and invasive strategies in CS complicating acute myocardial infarction. However, effect of sex on the prognosis of unselected CS remains controversial.
OBJECTIVES: The aim was to analyze the impact of sex on aetiology, management and prognosis of CS.
METHODS: The FRENSHOCK registry included all CS admitted in 49 French Intensive Care Units (ICU) and Intensive Cardiac Care Units (ICCU) between April and October 2016.
RESULTS: Among the 772 CS patients included, 220 were women (28.5%). Women were older, less smokers, with less history of ischemic cardiac disease (20.5% vs 33.6%) than men. At admission, women presented less cardiac arrest (5.5 vs 12.2%), less mottling (32.5 vs 41.4%) and higher LVEF (30 ± 14 vs 25 ± 13%). Women were more often managed via emergency department while men were directly admitted at ICU/ICCU. Ischemia was the most frequent trigger irrespective of sex (36.4% in women vs 38.2%) but women had less coronary angiogram and PCI (45.9% vs 54% and 24.1 vs 31.3%, respectively). We found no major difference in medication and organ support. Thirty-day mortality (26.4 vs 26.5%), transplant or permanent assist device were similar in both sexes.
CONCLUSION: Despite some more favorable parameters in initial presentation and no significant difference in medication and support, women shared similar poor prognosis than men. Further analysis is required to cover the lasting gap in knowledge regarding sex specificities to distinguish between differences and inequalities. NCT02703038.
The rapid test for recent HIV infection (RTRI) assay can distinguish between people who are recently-infected and those who are long-term HIV cases. This may help guide efforts to identify ongoing HIV transmission and direct prevention or treatment efforts. But, more research is needed on the impact of RTRI on the number of HIV+ individuals that can be identified through testing. Furthermore, not much is known about the impact that returning RTRI results may have on the occurrence of intimate partner violence.

A primary objective of this study is to compare the HIV testing yield among contacts of people newly diagnosed with HIV by recency testing result. The investigators will abstract routinely collected data from participant medical records and registers. In addition, a second primary objective of this study is to assess the incidence of intimate partner violence associated with the return of recency testing results among those classified as testing recent versus long-term. Index study participants newly diagnosed with HIV will be interviewed at the initial enrollment visit following HIV diagnosis and during follow-up visits at 1, 2, and 6-months using a health-related quality of life instrument and intimate partner violence questionnaire. Participants will be recruited from 60 high-volume facilities across all provinces in Rwanda during the evaluation period.
Oral Chinese herbal medicine (Gu Ben Hua Yu Fang decoction) and secukinumab will be used concurrently. The treatment duration for both secukinumab and oral Chinese herbal medicine is up to 16 weeks. Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg). Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice a day. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
Disclosed is a rapamycin nanoscale sustained-release agent prepared from the following raw materials in parts by weight: 1 part of rapamycin, 0.5-20 parts of soluble polymer carrier, 40-200 parts of organic solvent, and 400-20000 parts of aqueous phase. The rapamycin nanoscale sustained-release agent has a structure of nanomicelle and a particle size of 10-200 nm. The rapamycin nanoscale sustained-release agent presents low risk to blood vessels. The half-life of the rapamycin nanoscale sustained-release agent in the blood can be up to 50 hours or more. The rapamycin nanoscale sustained-release agent can directly reach the tumor-affected area. With continuous medication, the tumor regression rate can reach 50%.
ALED is a behavior change program. ALED offers different options to traditional exercise program to help participants overcome barriers to physical activity and increase their physical activity. The format is a 12-week program with 60-minute sessions that include a short lecture and group discussions to help participants set goals, decrease barriers to exercise, and find an activity they enjoy. The ALED program is conducted in the same format as MBCT+w, but participants are not taught the mind-body, walking or cognitive-behavioral skills. ALED will also use a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
Tobacco use remains a significant public health concern in the US, and youth are disproportionately affected. Among high school youth , 38% report lifetime cigarette use, and 9.3% report having smoked a whole cigarette before the age of 13. In Southeast Michigan, African-American youth are at disproportionate risk of engaging in tobacco use and co-occuring substance use and other risk behaviors. To address these significant public health concerns, we developed Storytelling 4 Empowerment (S4E), a targeted and tailored mobile-health (mHealth) application (app) intervention to be delivered in health clinic settings. The proposed research aims to develop culturally congruent and developmentally appropriate modules focused on tobacco use prevention and risk reduction to be included as part of the S4E mHealth app. The proposed research will also determine the preliminary efficacy of S4E in reducing tobacco use, alcohol and other drug use, sexual risk behaviors, and improving HIV/STI testing in a sample (n=50) of youth ages 13-21 living in Southeast Michigan.
<P>PROBLEM TO BE SOLVED: To obtain a solution having strong antioxidative power, a fiber product, a cosmetic, a food, etc.  <P>SOLUTION: Fossil coral and citric acid are put into a solution tank and the air in the tank is pressurized (under 2-3 atmospheric pressure) and minus voltage (from 1,000 volt to 2,500 volt) is applied to the interior of the tank. Thereby, the fossil coral is dissolved therein to provide the solution. The solution component is impregnated or attached to a fiber, feather, a wall paper, etc. The food, the cosmetic, an agricultural material, a soil-improving agent, a water quality-improving agent, a softening agent for washing, a bathing agent, a nonwoven paper, etc., each containing the solution component are also provided.  <P>COPYRIGHT: (C)2004,JPO
A maturation culture of immature oocytes will be performed in vitro during 36 hours. After IVM, mature oocytes will be vitrify in closed system by a semi-automatic method.
Cosmetic agents which contain a combination of special cyclical alcohols and specific menthyl compounds along with an antiperspirant or deodorant active ingredient. These agents have a high and long-lasting deodorizing effect. Also disclosed is a cosmetic product containing the cosmetic agent as contemplated herein, as well as at least one propellant. The use of agents as contemplated herein for treating body odor, as well as the use of a combination of cyclical alcohol and menthyl compound to increase the odor-inhibiting effect of cosmetic agents is also disclosed. Preferred menthyl compounds are menthyllactate, menthylacetate and pyroglutamic acid menthyl ester. Specified cyclic alcohols are 1-cyclohexylethanol, 2-methyl-5-cyclohexylpentanol and dimethylolcyclohexane. In an embodiment, the cyclical alcohol is 1-cyclohexylethanol, the menthyl compound is menthylacetate and aluminium chlorohydrate is used as the antiperspirant compound.
The scales applied to the intervention group on the first day, by sending the E-Health literacy scale form or phone link via Google on mobile devices. The symptoms of the patients in the control group will be evaluated at the end of the 1st day, 7th day, 14th day and 4th day. No intervention was planned for the patients in the control group during the follow-up. In the standard practice protocol, after patients are informed for follow-up and treatment at home, they are called by the Ministry of Health and family physicians for symptom follow-up. The standard hospital protocol does not include a scheduled training program, telephone monitoring, or web-based training. After collecting the data in the intervention group, the website will be opened to the use of the control group.
Chronic low back pain (CLBP) is one of the most ubiquitous and intractable problems in medicine and a significant source of patient suffering and disability, leading to opioid misuse and addiction. Previous neuromodulatory therapies for CLBP have focused primarily on spinal etiologies and intra-spinal mechanisms of pain transmission. However, existing pharmacological and neuromodulatory therapies have not been successful in treating CLBP. This project aims to address critical gaps and the unmet therapeutic needs of CLBP patients by using the Abbott Infinity DBS System; a next generation DBS device with directional steering capability implanted bilaterally in the subgenual cingulate cortex (SCC) to engage networks known to mediate the affective component of CLBP. The objective is to (1) Assess the preliminary efficacy of DBS of the SCC in the treatment of medically refractory CLBP; (2) Demonstrate the safety and feasibility of SCC DBS for CLBP; and (3) Develop diffusion tensor imaging (DTI)-based blueprints of response to SCC DBS for CLBP. The overall impact of this proof-of-concept pilot trial includes validation of the concept that suffering from CLBP results from pathological activity in affective brain networks, that these networks can be accurately engaged using a next-generation directional DBS device in a safe and feasible manner, and the discover of neuroimaging biomarkers of response to SCC DBS for CLBP.
An extract of hyssop (Gratiola officinalis) is prepared by (1) lixiviating powdered hyssop plant with a solvent comprising MeOH, EtOH, n-PrOH or iso-PrOH optionally diluted with water and completely evaporating the solvent by distillation leaving as residue a crude extract I, (2) boiling crude extract I with a solvent which is an aromatic or a cyclic hydrocarbon or with a chlorinated solvent decanting the hot solution and removing the solvent e.g. by evaporation under vacuum, preferably at 80 DEG C., to give a purified extract II, and (3) dissolving the purified extract II in water, extracting the solution thus obtained with an alkanol having 4 or 5 carbon atoms or a dialkyl ketone having 4 to 6 carbon atoms, separating the aqueous phase and removing the solvent from the organic phase e.g. by azeotropic distillation to give the purified extract III.  The solvent used in step (2) is preferably benzene, toluene, a xylene, a petroleum fraction of b. pt. range 55 DEG -130 DEG C., methylene chloride, dichloroethylene, chloroform or trichloroethane.  The purified extract III can be dissolved in MeOH and precipitated by the gradual addition of ether to give a pulverulent purified extract.  The extract of hyssop possesses a strong laxative action and a small toxicity and is used for the medication of human beings in the form of tablets and pills (which may be sugarcoated), granules and capsules, containing 10 to 100 mg. of the extract per unit.  Other laxatives and spasmolytics may also be present in the compositions.
The patient in supine position. Under complete aseptic conditions, a linear array transducer 5-12 MHz (Siemens ACUSON X300 Ultrasound System) will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
PURPOSE:To obtain an antibacterial adhesive member having an excellent antibacterial property, having no skin irritability and not coloring an adapting area, by laminating a copolymer of specific vinylsalicylic acid or methyl ester thereof and (meth)acrylic ester to a flexible carrier. CONSTITUTION:Since an antibacterial copolymer consisting of 5-50wt.% of a monomer composed of vinylsalicylic acid or ester thereof and 95-50wt.% of (meth)acrylic ester has desired coagulability, said copolymer can be used as the adhesive of an adhesive type drug member for external application. In order to further enhance coagulability, a monomer or polar monomer copolymerizable with said monomer is pref. compounded in a range of 10% or less by wt. of all of the monomers to be copolymerized with said monomers. The solution of this antibacterial copolymer is applied to a flexible carrier and dried to form the antibacterial copolymer layer on said carrier. The antibacterial adhesive member thus obtained is used as an emergency adhesive plaster or a roller bandage as it is. As the vinylsalicylic acid monomer, 3-vinylsalicylic acid, 4-vinylsalicylic acid and 5-vinylsalicylic acid are used.
The invention discloses a traditional Chinese medicine composition for treating infant herpetic stomatitis, and belongs to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine considers that infant herpetic stomatitis comes from spleen and stomach and mouths and tongues have sores as wind-heat is externally infected, attacks from the skin and attacks upwards to the mouth and tongues. Heat is retained in the heart and spleen, the myolemma is red and slight swelled, and the myolemma is ulcerated and concaved because of heat corrosion. Therefore, the composition is prepared from the following traditional Chinese medicines: unprepared rehmannia roots, roots of common peony, cape jasmine, lophatherum gracile, akebiaquinata, periostracum cicada, liquorice, coptis chinensis, reed rhizome, radices trichosanthis, poria cocos, semen plantaginis and talc. The medicines are boiled into a decoction with water and are taken by infants in sickness. Clinical experiment of years shows that the traditional Chinese medicine disclosed by the invention has good effects of clearing away heat and toxic materials, relieving swelling and pain, removing slough and promoting growth of tissue regeneration, has a good effect in treating infant herpetic stomatitis, and has the advantages of definite medicine effect, rapidness in taking effect, zero toxic or side effects, uneasiness in reoccurrence and the like.
Liquid biopsy, a noninvasive diagnosis that examines circulating tumor components in body fluids, is increasingly used in cancer management. An overview of relevant literature emphasizes the current state of liquid biopsy applications in cancer care. Biomarkers in liquid biopsy, particularly circulating tumor DNA (ctDNA), circulating tumor RNAs (ctRNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other components, offer promising opportunities for early cancer diagnosis, treatment selection, monitoring, and disease assessment. The implementation of liquid biopsy in precision medicine has shown significant potential in various cancer types, including lung cancer, colorectal cancer, breast cancer, and prostate cancer. Advances in genomic and molecular technologies such as next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR) have expanded the utility of liquid biopsy, enabling the detection of somatic variants and actionable genomic alterations in tumors. Liquid biopsy has also demonstrated utility in predicting treatment responses, monitoring minimal residual disease (MRD), and assessing tumor heterogeneity. Nevertheless, standardizing liquid biopsy techniques, interpreting results, and integrating them into the clinical routine remain as challenges. Despite these challenges, liquid biopsy has significant clinical implications in cancer management, offering a dynamic and noninvasive approach to understanding tumor biology and guiding personalized treatment strategies.
PURPOSE: A composition for enteric hard capsules and an enteric hard capsule manufactured by using the same are provided to enhance mechanical strength and transparency and to delay the salting out. CONSTITUTION: A composition for enteric hard capsules comprises 50-90 parts by weight of hydroxypropyl methylcellulose phthalate(HPMCP), 10-50 parts by weight of hydroxypropyl methylcellulose(HPMC), 0.1-2.5 parts by weight of water-soluble divalent base, and 3.5-7.5 parts by weight of extra alkaline chemicals. The content of each component is based on the sum total 100 parts by weight of the HPMC and the HPMCP. The HPMCP comprises 20-24 wt% of methoxy group, 6-10 wt% of hydroxy propoxy group, and 21-26 wt% of phthalyl, and has the dynamic viscosity of 48~66cSt. The water-soluble divalent base includes calcium hydroxide. The extra alkaline chemicals comprise ammonia, NaOH, potassium hydroxide or a combination thereof. The composition additionally includes 1-5 parts by weight of plasticizer based on the sum total 100 parts by weight of the HPMC and HPMCP. The composition additionally includes 0.05-0.5 parts by weight of emulsifier based on the sum total 100 parts by weight of the HPMC and HPMCP.